In terms of safety, Descartes-08 was characterized as well-tolerated during the study and long-term follow-up period.
Cartesian Therapeutics’ Descartes-08, an investigational autologous mRNA-engineered chimeric antigen receptor T-cell therapy (CAR-T) therapy for the treatment of autoimmune diseases including myasthenia gravis (MG), has demonstrated clinically meaningful improvements in the phase 2a portion of a clinical trial (NCT04146051) for MG.1
Among 7 patients in the phase 2a portion of the study who were treated with a single infusion of Descartes-08 each week for 6 weeks, all 7 continued to show marked and long-lasting clinical improvements across the MG Composite, MG Activities of Daily Living, Quantitative MG scores, and Quality of Life 15-revised instruments at 9 months after beginning treatment. Cartesian noted that none of these patients had been treated with new or increased MG-directed drugs while on-study. The 7 patients underwent assessment on the 4 aforementioned instruments again at 12 months of follow-up and 5 maintained clinically meaningful improvement.The 2 patients who had experienced loss of clinical effect at this time point were eligible for retreatment and 1 of these patients went forward with retreatment. The patient who was retreated showed a rapid improvement in clinical scores. Six months after beginning retreatment, the patient had minimal symptom expression and showed an ongoing improvement in clinical scores.
Furthermore, prior to beginning treatment 3 of the 7 patients had detectable anti-acetylcholine receptor (AChR) antibody levels. It was noted that at 6 months of follow-up, marked decreases in antiAChR antibody levels were observed in these patients. The observed decreases deepened at 9 months of follow-up and remained stable at 12 months of follow-up.
In terms of safety, Descartes-08 was characterized as well-tolerated during the study and long-term follow-up period. There were no cases of dose-limiting toxicities, cytokine release syndrome, or neurotoxicity reported. Cartesian noted that the patients were treated in an outpatient setting and that lymphodepleting chemotherapy was not used prior to treatment.
“The 12-month data build on the positive data reported earlier this year in The Lancet Neurology, underscoring the potential of Descartes-08 to drive deep and durable responses in patients with MG,” Milos Miljkovic, MD, the chief medical officer of Cartesian Therapeutics, said in a statement.1 “Notably, most patients maintained robust, clinically meaningful improvements across all 4 standard MG severity scores approximately 10 months after the last infusion. In addition, the lasting reductions in autoantibody titers are consistent with the observed clinical responses and the proposed mechanism of action for Descartes-08, supporting the deep and long-lasting effects observed in the study. As the first clinical trial using mRNA CAR-T to treat autoimmunity, the study also highlights the potential of our approach to expand the capabilities of cell therapy to address a variety of autoimmune diseases.”
A phase 2b double-blind randomized placebo-controlled portion of the same trial evaluating Descartes-08 in MG is also ongoing, with the first patient
Descartes-08 is comprised of patients’ own T-cells that have been modified ex-vivo with RNA to target B-Cell Maturation Antigen (BCMA). The use of RNA engineering is intended to avoid risks of genomic integration associated with DNA-based CAR-T therapies and to allow for control of pharmacokinetics.
Cartesian Therapeutics is one of several companies currently developing CAR-T therapies for the treatment of MG. In November 2023, Kyverna Therapeutics’ CD19-directed CAR-T therapy KYV-101
